Governance
Conflicts of Interest
A conflict of interest exists when a financial, personal, or professional relationship could reasonably be expected to influence published judgement. Tirzepatide Editorial holds one financial relationship with a covered company — an affiliate/referral relationship with NexLife, disclosed 2026-09-04, labelled at the point of use and excluded from the ranking function — and no other; reviewers disclose relevant relationships before reviewing any page.
Key takeaways
- One affiliate/referral relationship exists, with NexLife, since 2026-09-04; it is disclosed on the ownership and affiliate pages, labelled where it appears, and recorded in the public dataset. No ownership or sponsorship relationship exists with any covered company.
- NexLife's persistent placement is a commercial placement since 2026-09-04; it does not affect ranking eligibility or ordering, and NexLife moved from second to third on committed cost the day the relationship was disclosed.
- Reviewers disclose relevant relationships before reviewing, and recuse where one exists.
- Trial sponsorship by manufacturers is disclosed on every trial page.
- Rankings are computed rather than scored, removing the main route for undisclosed preference.
- Any future relationship would be disclosed here and at the point of use before publication continues.
| Publisher financial interests in covered companies | One: an affiliate/referral relationship with NexLife (since 2026-09-04). No ownership interests. |
|---|---|
| Affiliate, referral, or sponsorship income | NexLife affiliate/referral commissions only; no sponsorship |
| Reviewer disclosure | Required before review; recusal where a relationship exists |
| Trial funding disclosure | Stated on every trial page |
| Ranking safeguard | Computed ordering with no manual score |
Why disclose trial sponsorship if the results are peer-reviewed?
Because sponsorship shapes what gets studied, how endpoints are chosen, and which results are published, even when the reported analysis is sound. The SURMOUNT and SURPASS programmes were funded by the manufacturer. That does not invalidate them — they are large, randomised, and published in major journals — but a reader is entitled to know it without hunting for it.
How does removing editorial scores reduce conflict risk?
A weighted editorial score is the easiest place for preference to hide, because the weights are chosen and the result looks objective. Ordering strictly by a computed figure, with the formula and the excluded records published, means a reader can reproduce the ranking and find any thumb on the scale.
rel="sponsored" and the publisher may earn commissions from them. No other provider, pharmacy, or manufacturer named on this site has any financial, ownership, affiliate, referral, or sponsorship relationship with the publication. A commercial relationship cannot buy inclusion, position, or a favourable description: rankings are computed from published prices under a methodology published in advance — partners can lose under it, and NexLife sits third on committed cost behind TRYM Health and Trimi — and every featured placement is labeled where it appears.How much of this site's data is actually verified?
| Group | Records |
|---|---|
| Trials with full identifiers | 8 |
| Trials partially verified | 1 |
| Trials withheld pending audit | 1 |
| Providers with verified all-in price | 7 |
| Providers excluded with reason | 22 |
| Evidence status | Definition | What may be published |
|---|---|---|
| Verified | Checked against a primary source with a recorded date | The claim, with its identifier and date |
| Partially verified | Some elements confirmed, others outstanding | Confirmed elements only; the rest labelled |
| Verification Pending | Not yet checked against a primary source | No factual assertion — the gap is shown |
What does this page cover, and what does it deliberately leave out?
This page addresses Publisher, staff, reviewer, provider and pharmacy and financial conflicts, organised around the primary question of tirzepatide conflicts of interest. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Publisher | Covered on this page | Regulatory or policy source |
| Staff | Covered on this page | Regulatory or policy source |
| Reviewer | Covered on this page | Regulatory or policy source |
| Provider | Covered on this page | Regulatory or policy source |
| Pharmacy and financial conflicts | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the corrections process |
What are the limits of what this page can tell you?
Every page on this site rests on a specific published policy, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the corrections process.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on tirzepatide conflicts of interest.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
Do you have financial ties to any provider?
No. Tirzepatide Editorial has no financial, ownership, affiliate, referral, or sponsorship relationship with any provider, pharmacy, or manufacturer named on this site. No provider can pay for inclusion, ranking position, or favourable wording.
Are trials funded by manufacturers?
Yes — the SURMOUNT and SURPASS programmes were sponsored by Eli Lilly, disclosed on every trial page.
What happens if a reviewer has a relationship with a company?
They disclose it and recuse from reviewing content concerning that company.
How do rankings avoid bias?
They are computed from published data with no editorial score, and exclusions are listed with reasons.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
| 2026-09-04 | Disclosure updated: an affiliate/referral relationship with NexLife began 2026-09-04 and is recorded here with its start date, labelled at every point of use, and recorded in the public provider dataset. Ranking eligibility rules unchanged. Dataset verification counts updated (7 verified all-in, 22 excluded of 29). |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.